首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2019年?8期 遗传性肝病的诊断 => 其他 =>水飞蓟制剂预防性治疗..
水飞蓟制剂预防性治疗抗结核药物性肝损伤效果的Meta分析
Clinical effect of Silybum marianum preparation in the prophylactic treatment of antitubercular agent-induced liver injury: A Meta-analysis of randomized controlled trials
文章发布日期:2019年07月05日  来源:  作者:陶娌娜,曲晓宇,张越,等  点击次数:162次  下载次数:10次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的评估水飞蓟制剂在预防抗结核药物性肝损伤(ATB-DILI)中的作用。方法检索MEDLINE、PubMed、Embase和Cochrane对照试验中心注册库(CENTRAL)截至2018年11月30日,水飞蓟制剂与安慰剂相比预防ATB-DILI的随机对照试验研究。所有统计分析均使用STATA12.0软件进行。使用具有95%可信区间(95%CI)的标准化均值差(SMD)和相对危险度(RR)来评估水飞蓟制剂的作用。纳入研究的质量根据Cochrane手册进行评估。使用漏斗图和Egger’s测试评估发生偏倚。采用敏感性分析以评估每项研究对整体效应大小的影响。结果共纳入5项随机对照试验的1198例患者(585例使用水飞蓟制剂,613例使用安慰剂)。水飞蓟制剂在第4周显着降低了ATB-DILI的发生风险(RR=0.33,95%CI:0.15~0.75,P=0.008)。此外,水飞蓟制剂对接受抗结核药物治疗的患者肝功能有保护作用(ALT: SMD=-0.15,95%CI:-0.24~-0.07,P<0.001; AST:SMD=-0.14,95%CI:-0.23~-0.06,P= 0.001; ALP:SMD=-0.12,95%CI:-0.20~-0.03,P=0.008)。 水飞蓟制剂和安慰剂不良反应发生风险相当 (RR=1.09,95%CI:0.86~139,P=0.47)。结论水飞蓟制剂的预防性治疗有助于结核病患者开始治疗后4周显着降低ATB-DILI的发生风险。此外,水飞蓟制剂还能显着改善抗结核药物治疗患者的肝功能。
【Abstract】:ObjectiveTo evaluate the clinical effect of Silybum marianum preparation in the prophylactic treatment of antitubercular agent-induced liver injury (ATB-DILI), since there have always been controversies over the development of Silybum marianum preparation for the prophylactic treatment of ATB-DILI. MethodsMEDLINE, PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched for randomized controlled trials (RCTs) on Silybum marianum preparation versus placebo in preventing ATB-DILI published up to November 30, 2018. STATA 12.0 software was used for statistical analyses. Standardized mean difference (SMD) and risk ratio (RR) with 95% confidence intervals (CI) were used to evaluate the effect of Silybum marianum preparation. The Cochrane handbook was used to assess the quality of RCTs, and funnel plots and Egger’s tests were used to evaluate publication bias. A sensitivity analysis was conducted to assess the influence of each RCT on overall effect. ResultsA total of five RCTs with 1198 patients were included, and among these patients, 585 received Silybum marianum preparation and 613 received placebo. Silybum marianum preparation significantly reduced the risk of the onset of ATB-DILI at week 4 (RR=0.33, 95%CI: 0.15-0.75, P=0.008). In addition, Silybum marianum preparation had a protective effect on liver function in patients receiving antitubercular agents (alanine aminotransferase: SMD=-0.15, 95%CI: -0.24 to -0.07, P<0.001; aspartate aminotransferase: SMD=-0.14, 95%CI: -0.23 to -0.06, P=0.001; alkaline phosphatase: SMD=-0.12, 95%CI: -0.20 to-0.03, P=0.008). Silybum marianum preparation had a similar risk of adverse events as placebo (RR=1.09, 95%CI: 0.86-1.39, P=0.47). ConclusionIn patients with tuberculosis, prophylactic treatment with Silybum marianum preparation can significantly reduce the risk of the onset of ATB-DILI after 4 weeks of treatment. In addition, Silybum marianum preparation can also improve the liver function of patients treated with antitubercular agents.
【关键字】:化学性与药物性肝损伤; 抗结核药; 水飞蓟素; Meta分析(主题)
【Key words】:chemical and drug induced liver injury; antitubercular agents; silymarin; Meta-analysis as topic
【引证本文】:TAO LN, QU XY, ZHANG Y, et al. Clinical effect of Silybum marianum preparation in the prophylactic treatment of antitubercular agent-induced liver injury: A Meta-analysis of randomized controlled trials[J]. J Clin Hepatol, 2019, 35(8): 1775-1781. (in Chinese)
陶娌娜, 曲晓宇, 张越, 等. 水飞蓟制剂预防性治疗抗结核药物性肝损伤效果的Meta分析[J]. 临床肝胆病杂志, 2019, 35(8): 1775-1781.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright ? 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

ag捕鱼王试玩|官网